At the time of writing, Longeveron Inc [LGVN] stock is trading at $1.99, up 4.19%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LGVN shares have gain 13.71% over the last week, with a monthly amount drifted -0.50%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Longeveron Inc [NASDAQ: LGVN] stock has seen the most recent analyst activity on December 06, 2024, when ROTH MKM initiated its Buy rating and assigned the stock a price target of $10.
For the past year, the stock price of Longeveron Inc fluctuated between $0.77 and $13.50. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Longeveron Inc [NASDAQ: LGVN] shares were valued at $1.99 at the most recent close of the market. An investor can expect a potential return of 402.51% based on the average LGVN price forecast.
Analyzing the LGVN fundamentals
According to Longeveron Inc [NASDAQ:LGVN], the company’s sales were 1.85M for trailing twelve months, which represents an 415.33% jump. Gross Profit Margin for this corporation currently stands at 0.47% with Operating Profit Margin at -9.55%, Pretax Profit Margin comes in at -9.76%, and Net Profit Margin reading is -9.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -1.42 and Total Capital is -0.66.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8667 points at the first support level, and at 1.7433 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.1767, and for the 2nd resistance point, it is at 2.3633.
Ratios To Look Out For
It is important to note that Longeveron Inc [NASDAQ:LGVN] has a current ratio of 7.67. Further, the Quick Ratio stands at 7.67, while the Cash Ratio is 7.35. Considering the valuation of this stock, the price to sales ratio is 17.03, the price to book ratio is 1.15.
Transactions by insiders
Recent insider trading involved Baluch Khoso, Director, that happened on Dec 02 ’24 when 1250.0 shares were sold. Director, Baluch Khoso completed a deal on Nov 27 ’24 to buy 1250.0 shares. Meanwhile, Chief Scientific Officer Hare Joshua bought 0.11 million shares on Apr 10 ’24.
